Clin2
NCT07588568Possibly a fitNot yet recruiting

Upadacitinib for eosinophilic esophagitis resistant to steroids

EoEEosinophilic EsophagitisEosinophilic Esophagitis (EoE)

Treatments studied

Part of Blood & lymphatic, Digestive system, Immune system & allergy clinical trials.

This study tests whether a medication called upadacitinib can help people with eosinophilic esophagitis (a condition where too many white blood cells called eosinophils build up in the food tube) who are not getting better with their current steroid treatment. The medication works by reducing inflammation in the esophagus.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
52 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • Age 18–65 years
  • Confirmed diagnosis of eosinophilic esophagitis and currently taking topical steroid medication (budesonide or fluticasone) for at least 8 weeks
  • Active symptoms like trouble swallowing, heartburn, chest pain, or abdominal pain in the past 4 weeks, confirmed by endoscopy showing high eosinophil counts despite steroid treatment
  • Able to swallow pills and willing to keep taking all current EoE medications unchanged throughout the study
  • No history of shingles, herpes simplex, HIV, tuberculosis, recent infections, or certain heart/blood clot conditions
  • Not pregnant, not planning pregnancy, and willing to use non-estrogen birth control if of childbearing age

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05730933Recruiting
Study to help adults stick to eosinophilic esophagitis treatment

This trial tests an intervention meant to improve how well adults with eosinophilic esophagitis (EoE) follow their ongoing treatment plan. It may help you stay on your medicine and get better symptom control by making adherence easier.

Amsterdam
NCT05608681Recruiting· Phase 1/Phase 2
Study drug for adults with eosinophilic esophagitis (EoE

This Phase 1/2 study tests EP-104GI in adults with eosinophilic esophagitis (EoE), a condition where certain immune cells cause inflammation in the food pipe. It may help improve symptoms and inflammation, and the study also includes a part where people who do well can switch to the active drug.

Sydney, New South Wales
NCT07012928Recruiting
Study of immune responses in eosinophilic esophagitis patients

This study looks at how the immune system and the esophageal barrier function in people with eosinophilic esophagitis (EoE) compared to those without. It involves taking biopsies during an upper endoscopy to understand the disease better. The results may help improve treatments for EoE.

Amsterdam, North Holland
NCT06684522Recruiting· Early Phase 1
Upadacitinib for stubborn eyelid dermatitis

This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.

Chicago, Illinois
NCT07700446Not yet recruiting· Phase 4
Testing a second round of upadacitinib for ulcerative colitis

This trial tests if a higher dose of upadacitinib can help people with ulcerative colitis who stopped responding to the 30 mg daily dose. It aims to see if re-inducing with a stronger dose can bring back symptom control.

NCT06780683Recruiting
Testing upadacitinib for inflammatory bowel disease

This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.

Guangzhou, Guangdong

Hear when a new Eosinophilic Esophagitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.